Biolab Sanus is a Brazilian pharmaceutical company headquartered in São Paulo, Brazil, specializing in the development and manufacturing of medications for neurological and psychiatric disorders. The company has established itself as a leading provider of central nervous system (CNS) medications in the Brazilian market.
Founded in 1997, Biolab has grown to become one of the most important domestic pharmaceutical companies in Brazil, with a strong focus on generics, branded generics, and innovative formulations for neurological conditions.
| Attribute |
Details |
| Headquarters |
São Paulo, Brazil |
| Founded |
1997 |
| Focus Areas |
Neurology, Psychiatry, Cardiology, Pulmonology |
| Products |
100+ SKUs across therapeutic areas |
| Market |
Brazil, Latin America |
| Employees |
1,500+ |
| Regulatory |
ANVISA approved |
Biolab Sanus is a major player in the Brazilian generic drug market, producing affordable versions of widely prescribed medications:
- Cost-effective alternatives to brand-name medications
- Generic versions of CNS drugs including anticonvulsants and antidepressants
- Generic Parkinson's and Alzheimer's medications
¶ Branded Generics
The company also markets branded generic products, which offer a balance between affordability and brand recognition:
- Established brand presence in the Brazilian pharmaceutical market
- Quality Assurance: All products manufactured under strict ANVISA guidelines
- Distribution network spanning all Brazilian states
Biolab invests in novel drug delivery systems:
- Transdermal patches: Extended-release formulations for neurological conditions
- Oral dispersible tablets: For patients with swallowing difficulties
- Controlled-release formulations: For sustained therapeutic effect
Biolab markets several medications for Alzheimer's disease management:
These medications form the standard of care for Alzheimer's disease symptom management, targeting cholinergic deficiency and glutamatergic excitotoxicity.
The company provides comprehensive dopaminergic medications for Parkinson's disease:
| Medication |
Class |
Formulation |
| Levodopa/Carbidopa |
Dopamine precursor |
Tablet, CR Tablet |
| Pramipexole |
D2 receptor agonist |
Tablet, ER Tablet |
| Rotigotine |
D2/D3 agonist |
Transdermal patch |
| Entacapone |
COMT inhibitor |
Tablet |
| Selegiline |
MAO-B inhibitor |
Tablet, Patch |
- Anticonvulsants: For seizure disorders and neuropathic pain
- Antidepressants: SSRIs, SNRIs, and tricyclic medications
- Antipsychotics: For schizophrenia and bipolar disorder
- Anxiolytics: For anxiety disorders
- Amantadine: NMDA antagonist, anti-dyskinesia
- Trihexyphenidyl: Anticholinergic for tremor
¶ Research and Development
Biolab's R&D facilities include:
- Formulation Development: Tablet, capsule, and transdermal patch development
- Analytical Laboratories: Quality control and method development
- Stability Testing: Accelerated and real-time stability studies
- Bioequivalence Studies: For generic drug approval
Current R&D focus areas:
- Novel formulations of existing CNS drugs
- Transdermal delivery systems for neurological conditions
- Fixed-dose combinations for neurological disorders
- Generic versions of recently patented CNS medications
- Pediatric formulations for neurological medications
- Rotigotine patch technology for continuous dopaminergic stimulation
Biolab operates GMP-compliant manufacturing facilities:
- Solid dosage: Tablets, capsules, sachets
- Transdermal: Patches and topical formulations
- Liquid formulations: Syrups and suspensions
- Quality control: Full analytical testing capabilities
- ANVISA (Brazilian Health Regulatory Agency) certification
- ISO 9001:2015 quality management
- Regular regulatory inspections
- Full traceability of raw materials
Biolab Sanus is recognized in Brazil as:
- A leading generic CNS medication provider
- A trusted brand among healthcare professionals
- A strategic partner for international companies seeking Brazilian market access
- SUS (Sistema Único de Saúde): Reliable supplier to the Brazilian public healthcare system
- Private Market: Strong presence in private pharmacies and hospitals
- Health Insurance: Partnerships with major Brazilian health insurers
Brazil represents the largest pharmaceutical market in Latin America:
- Population: 200+ million
- Pharmaceutical market: $15+ billion annually
- Generic penetration: Growing steadily
- Regulatory environment: ANVISA oversight
Key competitors in the Brazilian CNS market:
The Brazilian pharmaceutical market represents the largest in Latin America, with significant implications for neurodegenerative disease treatment access:
- Demographic trends: Aging population increases demand for AD and PD therapies
- Healthcare access: Universal healthcare system creates large patient pool
- Regulatory pathway: ANVISA provides pathway for regional expansion
- Manufacturing hub: Brazil serves as regional manufacturing center